Search

Displaying results 1661 - 1670 of 7499 in total
  1. Drug

    Gadofosveset trisodium

    go.drugbank.com/drugs/DB06705
    Approved

    The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels. … Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels.

  2. Drug

    Fingolimod

    go.drugbank.com/drugs/DB08868
    ApprovedInvestigational

    It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.

  3. Drug

    Oxaprozin

    go.drugbank.com/drugs/DB00991
    Approved

    Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  4. Drug

    Idursulfase

    go.drugbank.com/drugs/DB01271
    ApprovedInvestigational

    Idursulfase is produced by recombinant DNA technology in a human cell line. … The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures.

  5. Drug

    Methimazole

    go.drugbank.com/drugs/DB00763
    ApprovedInvestigational

    [A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred … in pregnancy due to a perceived lower risk of teratogenic effects.

  6. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease. … Pompe disease is characterized by progressive muscle weakness and loss of motor function, including respiratory muscle weakness, which leads to premature death and debilitating effects on people’s lives

    Synonyms: Neo-recombinant human acid alpha-glucosidase
  7. Drug

    Fenbufen

    go.drugbank.com/drugs/DB08981
    Approved

    Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation. … Fenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  8. Drug

    Fremanezumab

    go.drugbank.com/drugs/DB14041
    ApprovedInvestigational

    [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.

  9. Drug

    Methenamine

    go.drugbank.com/drugs/DB06799
    ApprovedInvestigationalVet approved

    Methenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane.

    Mixtures: UR N-C Urinary Antiseptic, Non Toxic Disinfectant
  10. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    By improving the three-year survival rate from 55% to 84%,[L32288] and considering the lack of alternative therapies available, fosdenopterin appears poised to become a standard of therapy in the management … [A230088] Fosdenopterin was approved by the FDA on Februrary 26, 2021, for the reduction of mortality in patients with MoCD type A,[L32163] becoming the first and only therapy approved for the treatment